Valuation: Theraclion

Market Cap 47.15M 54.94M 44.26M 40.42M 76.29M 5.24B 76.66M 524M 203M 2.64B 206M 202M 8.76B P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 55.01M 64.09M 51.63M 47.15M 88.99M 6.11B 89.42M 611M 237M 3.08B 241M 235M 10.21B EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
39.01%
Yield 2024 *
-
Yield 2025 -
1 day-1.00%
1 week-1.00%
Current month+9.59%
1 month+7.22%
3 months+10.00%
1 week 0.59
Extreme 0.594
0.62
1 month 0.54
Extreme 0.542
0.63
Current year 0.44
Extreme 0.436
0.93
1 year 0.44
Extreme 0.436
0.93
3 years 0.44
Extreme 0.436
0.93
5 years 0.44
Extreme 0.436
0.93
10 years 0.44
Extreme 0.436
0.93
Manager TitleAgeSince
Chief Executive Officer - 24/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 22/06/2021
Director/Board Member - 28/01/2022
Director/Board Member - 29/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-1.00% - - 54.09M
+0.89%+3.29%+29.73%+17.01% 232B
-0.28%+1.83%+4.42%-15.72% 152B
-0.38%-6.86%-21.90%+24.49% 131B
-3.39%-7.38%-54.72%-5.10% 72.26B
-0.10%-1.63%+11.70%+19.18% 52.38B
-1.11%-1.80%-16.89%-13.58% 51.57B
+0.20%-0.21%+31.09%+29.58% 43.71B
-0.07%-0.40%+39.86%+51.51% 40.72B
-0.38%+2.19%-17.35%+46.41% 34.13B
Average -0.56%+0.04%+0.66%+17.09% 90.02B
Weighted average by Cap. -0.25%-0.08%+3.55%+11.96%

Financials

2024 2025
Net sales 830K 967K 779K 712K 1.34M 92.26M 1.35M 9.22M 3.57M 46.54M 3.63M 3.55M 154M 652K 760K 612K 559K 1.05M 72.45M 1.06M 7.24M 2.81M 36.55M 2.85M 2.79M 121M
Net income -5.76M -6.71M -5.4M -4.94M -9.31M -640M -9.36M -63.95M -24.78M -323M -25.18M -24.64M -1.07B -5.69M -6.63M -5.34M -4.88M -9.21M -632M -9.25M -63.2M -24.49M -319M -24.89M -24.35M -1.06B
Net Debt 3.41M 3.97M 3.2M 2.92M 5.52M 379M 5.54M 37.89M 14.68M 191M 14.92M 14.6M 633M 7.85M 9.15M 7.37M 6.73M 12.7M 873M 12.76M 87.22M 33.8M 440M 34.35M 33.6M 1.46B
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36
Date Price Change
26/08/26 €0.5940 -1.00%
25/08/26 €0.6000 -1.15%
24/08/26 €0.6070 0.00%
21/08/26 €0.6070 -1.30%
20/08/26 €0.6150 +2.50%

Annual profits - Rate of surprise